New Prostate Cancer Therapy Shows Early Survival Promise
Adults with metastatic prostate cancer saw an 80% two-year survival rate in a small, preliminary clinical study.
Updated on Oct. 24, 2026 in Cancer
In a small phase 1 study of 15 patients with metastatic prostate cancer, a novel treatment combining tumor cryolysis with immunomodulator delivery showed promising survival rates. The 24-month overall survival rate reached 80% with minimal severe side effects.
Why it matters
This approach aims to improve prostate cancer treatment by using partial cryolysis to release specific tumor antigens while bolstering the immune system's response. The findings are being further investigated in a larger phase 2 trial to confirm these preliminary results.
This phase 1 trial enrolled 15 patients with metastatic prostate cancer, reporting an 80% overall survival rate at 24 months during a 29.6-month median follow-up. While preliminary, 95% of adverse events were grade 1 to 2, with no grade 3 or 4 immune-related complications observed.
The details
The SYNC-T Therapy SV-102 procedure utilizes partial tumor cryolysis to release tumor-specific antigens without destroying the entire tumor mass. This process is paired with the intratumoral delivery of a fixed-dose immunomodulator to promote the transport of agents into tumor-draining lymph nodes. By stimulating the immune system in this targeted way, the therapy seeks to enhance the body's ability to combat metastatic disease.
Timeline
October 23-27, 2026: Phase 1 results were presented at the ESMO Congress 2026.
Health Landscape
This approach shifts the treatment paradigm from systemic therapy to localized antigen stimulation for metastatic prostate cancer. These findings build upon the ongoing LEGION-100 trial to establish whether this technique can reliably improve long-term outcomes in larger patient cohorts.
While these results are early and limited to a very small group, they offer a new perspective on managing metastatic prostate cancer through immune-targeting procedures. Patients interested in how these types of clinical trials might fit into their care plan should discuss the options with their oncologist.
The takeaway
Preliminary data suggests that combined cryolysis and immunotherapy may safely improve survival for some with advanced prostate cancer. Patients and their doctors can keep track of outcomes from the ongoing LEGION-100 study to see if these early benefits hold true in a larger population.
Further reading
Learn more about evolving treatment approaches in Cancer.
